CELLINK AB (publ) (“CELLINK” or the “Company”) announced on June 18 that the Company has successfully completed a directed share issue of 550,000 new shares of series B (corresponding to approximately 6.5 per cent of the total number of outstanding shares in the Company) at a subscription price of SEK 270.00 per share, thus raising gross proceeds of SEK 148.5 million.
The net proceeds of the Directed Issue are intended to be used to potentially acquire a fast-growing (revenue CAGR 2016-2018 of 61 per cent) German laboratory equipment company active in the same niche as CELLINK with complimentary products and clear synergies between the two companies.
The Issue was heavily oversubscribed and in addition to participation from existing shareholders, several new institutional investors subscribed in the Issue.
CELLINK is the leading 3D-bioprinter provider and bioink company in the world.
Carnegie acted as sole bookrunner in the transaction.